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Abstract 
 
Current word count: 150, plus headings 
 
Background and Objective: To determine factors predicting ocriplasmin 
response in patients with symptomatic vitreomacular adhesion (VMA).  
 
Patients and Methods: Combined analysis of 2 multicenter, prospective, 
randomized, double-blind, trials of intravitreal ocriplasmin 125µg injection vs 
placebo. Patients had vitreomacular traction with or without a full-thickness 
macular hole (FTMH). Multivariate logistic regression was used to determine 
factors influencing treatment response (complete VMA release [day 28] and 
nonsurgical FTMH closure [month 6]). 
 
Results: Younger age, presence of FTMH (odds ratio [OR]=2.1; 95% confidence 
interval [CI]: 1.1, 3.7), VMA diameter ≤1500μm (OR=4.9; 95%CI: 2.0, 12.4), 
phakic lens status (OR=2.8; 95%CI: 1.5, 5.2), and absence of epiretinal 
membrane (OR=4.1; 95%CI: 2.2, 7.9), predicted VMA resolution. FTMHs with 
apical diameter ≤250μm were more likely to close than larger holes (58.3% vs 
24.6%; P=0.013). Both size groups had significantly greater chance of VMA 
resolution and FTMH closure vs controls.  
 
Conclusion: Ocriplasmin is most effective in younger patients with focal VMA 
and without an epiretinal membrane.   
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Introduction 
 
Vitreomacular traction (VMT) occurs in the context of perifoveal vitreous 
detachment, where residual foveal adhesion leads to distortion of the foveal 
architecture.1 Minor degrees of anatomic disturbance are compatible with normal 
vision, but if the traction progresses it can lead to troublesome metamorphopsia 
and blurred vision.2 Traction can also progress to a full-thickness macular hole 
(FTMH).1-4 
 
The current standard of care for VMT is either observation or pars plana 
vitrectomy. Observation is usually appropriate for patients who are either 
asymptomatic or mildly symptomatic, and some cases may resolve 
spontaneously over time.5,6 In the pre-optical coherence tomography (OCT) era, 
a natural history study found that only 11% of cases resolved over 5 years, with 
almost two-thirds of eyes losing at least two Snellen lines over this time frame.7 
In a more recent retrospective chart review of 106 eyes (81 patients) followed 
with spectral-domain OCT for a mean duration of 23 months, VMA was found to 
resolve spontaneously in 32% of eyes.8 
 
Pars plana vitrectomy is highly effective at relieving VMT, but the visual acuity 
(VA) gains may be modest, and vitrectomy is not without risk. A meta-analysis of 
vitrectomy for VMT reported that only one-third of eyes gained at least two 
Snellen lines.9 Postoperative retinal detachment occurred in 4.6% of eyes, and 
63% of phakic eyes developed cataract.9  
 
More recently, Stalmans et al reported a Phase 3, double-masked, placebo-
controlled study of ocriplasmin for the treatment of VMT.10 Ocriplasmin (Jetrea®, 
ThromboGenics NV, Leuven, Belgium)11,12 is a truncated form of plasmin, 
designed to liquefy the vitreous and resolve vitreomacular adhesion (VMA).13-15 
Following a single intravitreal injection of ocriplasmin 125 µg, 26.5% of eyes had 
complete resolution of VMA at the 28 day primary endpoint, vs 10.1% of the 
control (placebo) eyes.10 In eyes with coexisting FTMHs, 40.6% had hole closure 
by day 28, compared with 10.6% in the placebo group. There was a favorable 
safety profile, with many of the adverse events attributable to successful 
posterior vitreous detachment (PVD).10  
 
The combined pivotal trial of ocriplasmin met its primary endpoint, with 
significantly greater VMA resolution in the ocriplasmin group.10 A predefined, 
wide-ranging subgroup analysis of one or more of the 15 baseline variables was 
undertaken in relation to the primary and some of the secondary outcomes. This 
suggested that there were five factors that may help predict a positive anatomic 
response to ocriplasmin, namely age younger than 65 years, eyes without an 
epiretinal membrane (ERM), eyes with a FTMH, phakic eyes, and eyes with a 
focal VMA ≤1500 μm.16 Macular holes with an apical diameter of ≤250 μm were 
more likely to achieve nonsurgical closure than larger FTMHs. Visual acuity was 
more likely to improve in patients younger than 65 years and in eyes with a lower 
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best-corrected visual acuity at baseline. The initial subgroup analyses16 were not 
designed to provide detailed or targeted outcome data in those eyes identified as 
being potentially more responsive to ocriplasmin. We therefore aimed to 
undertake a post hoc best-responder analysis to refine our understanding of the 
outcomes in eyes thought most likely to respond to ocriplasmin, and thereby 
generate assumptions and hypotheses that can be tested in further definitive 
trials.  
  
 
Patients and Methods 
  
Details of the patient population, study design, and efficacy assessments for the 
two multicenter, randomized, double-masked, placebo-controlled, Phase 3 
studies (TG-MV-006, NCT00781859 and TG-MV-007, NCT00798317) have been 
published.10 Data from both trials were pooled for a prespecified combined 
analysis. The trials recruited adult participants with OCT-confirmed VMA, and 
those with FTMH of up to 400 µm, provided the FTMH occurred in association 
with VMA. Best-corrected Early Treatment of Diabetic Retinopathy Study 
(ETDRS) VA had to be at least 20/25 in the study eye. Epiretinal membranes 
were not excluded. In total, 652 patients (652 eyes) were randomized to receive 
a single intravitreal injection of ocriplasmin 125 μg in a 0.10-mL volume, or a 
placebo injection containing the same vehicle and fluid volume. Institutional 
review board or ethics committee approval was obtained for each participating 
site, and all participants provided written informed consent. The studies adhered 
to the tenets of the Declaration of Helsinki. 
 
Participants underwent a full ophthalmic examination and an OCT at baseline, 
then at 7, 14, 28, 90, and 180 days after injection. A central OCT reading center 
determined if VMA or macular hole was present or absent, at each visit.  
 
To evaluate which baseline characteristics would predict the primary efficacy 
endpoint (VMA resolution at day 28) and non-surgical FTMH closure at month 6, 
multivariate logistic regression models were built. Although a subgroup analysis 
was preplanned, it was post hoc with respect to the original analyses of the 
individual trials (TG-MV-006 and TG-MV-007), which did not incorporate a 
subgroup analysis. The demographic covariates analyzed for their effects on the 
two efficacy endpoints included one or more of the following: age (<65 years, 65 
to 75 years, and >75 years); gender; geographic region (US vs EU); race (white 
vs non-white); and body mass index (BMI <25 kg/m2 vs ≥25 kg/m2). Covariates 
for baseline disease characteristics included one or more of the following: 
presence/absence of ERM; diameter of focal VMA (>1500 µm vs ≤1500 µm); 
presence/absence of FTMH; lens status (phakic vs pseudophakic); 
presence/absence of diabetic retinopathy; expected need for vitrectomy at 
baseline (yes vs no); and VA (<65 letters, 65 to 75 letters, and >75 letters). 
Additional baseline variables were assessed for the FTMH closure endpoint 
including maximum FTMH base diameter, measured at the retinal pigment 
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epithelium (>600 µm vs ≤600 µm), and the apical diameter (>250 µm vs ≤250 
µm). Macular hole width was determined by taking the minimal intraretinal width 
measurements, roughly parallel to the retinal pigment epithelium (RPE), for each 
line scan where a full-thickness defect was present. The largest width recorded 
was used as the macular hole width measurement for the studies. Figure 1 
shows OCT images illustrating how eyes were classified. 
 
Covariate evaluations were first performed in a univariate manner by adding the 
covariates individually to the model. A 0.05 level was considered significant. If 
the covariate was not significant at the 0.05 level (type 3 test), it was not included 
in the final multivariate model. The variables of treatment and study (TG-MV-006 
vs TG-MV-007) were always included in the univariate and multivariate models. 
Covariates found significant in the multivariate model were then defined as 
predictive; their corresponding odds ratios (ORs) are presented. The ORs were 
computed with their 95% confidence interval (CI). Statistical analyses were 
performed using SAS® version 9.1.3.  
 
Results 
 
Demographic and baseline characteristics 
Of the 652 participants in studies TG-MV-006 and TG-MV-007, 464 were 
randomized to receive an intravitreal ocriplasmin injection and 188 received an 
intravitreal placebo injection.10 The study groups had similar demographics and 
baseline disease characteristics, except that the ocriplasmin group had a higher 
percentage of pseudophakic eyes (37.1% vs 28.2% for ocriplasmin and placebo, 
respectively). Baseline demographic and disease characteristics have been 
previously published.16   
 
Baseline predictors of VMA resolution  
Resolution of VMA at day 28 (the primary endpoint) was achieved in significantly 
more patients treated with ocriplasmin than with placebo (26.5% vs 10.1%; 
P<0.001).10 The significance of this treatment effect was confirmed by a 
multivariate logistic regression analysis. In the multivariate model adjusted for 
baseline covariates, treatment with ocriplasmin had a significant effect on the 
proportion of patients achieving VMA resolution at day 28 (P<0.001; OR=6.0; 
95% CI: 3.2, 11.4).  
 
Multivariate logistic regression model found that age was predictive of VMA 
resolution (type 3 test, P<0.001). Younger patients were more likely to have a 
VMA release than older patients. Resolution of VMA occurred in 38/80 (47.5%) 
ocriplasmin-treated patients aged <65 years vs 85/384 (22.1%) of those aged 
≥65 years. In both age groups, VMA resolution was significantly more common in 
the ocriplasmin group than in the placebo group with 10/43 (23.3%) placebo-
treated patients aged <65 years responding vs 9/145 (6.2%) of those aged ≥65 
years. 
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The multivariate logistic regression model also found that anatomic features 
significantly predictive of VMA resolution included the presence of FTMH 
(OR=2.053; 95% CI: 1.126, 3.742; P=0.019), VMA diameter ≤1500 μm 
(OR=4.944; 95% CI: 1.965, 12.435; P<0.001), phakic lens status (OR=2.824; 
95% CI: 1.536, 5.192; P<0.001), and absence of an ERM (OR=4.149; 95% CI: 
2.183, 7.937; P<0.001) (Figure 2). The percentages of participants that achieved 
VMA resolution at day 28 in each of the independently predictive covariate 
subgroups are shown in Figure 3. Across these subgroups, VMA resolution was 
achieved in 50.0% of ocriplasmin recipients and 25.5% of placebo recipients. 
Treatment differences in favor of ocriplasmin were observed across all 
subgroups compared with controls.  
 
Baseline predictors of FTMH closure 
Across the two studies, the proportion of participants who achieved nonsurgical 
FTMH closure at day 28 was significantly higher in the ocriplasmin group (40.6%) 
than in the vehicle group (10.6%) (OR=5.94; 95% CI: 2.09, 21.01; P<0.001).10 
Similar results were observed at month 6 (40.6% vs 17.0%; OR=3.45; 95% CI: 
1.40, 9.49; P=0.004). Multivariate analysis demonstrated that treatment with 
ocriplasmin was an independent predictor of FTMH closure by month 6 
(OR=4.267; 95% CI: 1.714, 10.623; P=0.002 [Figure 4]). Recruitment to either of 
the pivotal trials (TG-MV-006 or TG-MV-007) did not affect outcome. 
 
Using the multivariate model, eyes with an FTMH apical diameter ≤250 μm were 
more likely to achieve nonsurgical closure by month 6 than eyes with a hole >250 
μm (58.3% vs 24.6%, respectively; OR=2.724; 95% CI: 1.237, 6.001; P=0.013 
[Figures 4 and 5]). The forest plot (Figure 4) shows that eyes with a macular hole 
base diameter (Max MH width at RPE) ≤600 µm tended to do better than larger 
holes, but this did not reach significance. However, both size groups had a 
greater chance of FTMH closure than controls, with a treatment difference of 
38.3% (95% CI: 17.3, 59.3) for FTMHs ≤250 μm and 10.9% (95% CI: −7.3, 29.1) 
for those >250 μm. The percentages of patients that achieved macular hole 
closure at month 6 in each of the FTMH baseline width subgroups are shown in 
Figure 5. 
 
 
Discussion 
 
Ocriplasmin is a first-in-class drug that leads to a significantly higher rate of VMA 
resolution compared with placebo injection. However, it would be helpful for the 
clinician to know which patients respond best to treatment with ocriplasmin. 
Targeted case selection is likely to increase the rate of VMA resolution that 
occurs following ocriplasmin injection. For patients with VMT, our analysis 
suggests that ocriplasmin is most effective for eyes with focal VMA (≤1500 µm) 
and without an ERM. For eyes with FTMH, closure is more likely if the apical hole 
diameter is ≤250 µm. 
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The better response in eyes with focal VMA and no ERM is biologically plausible. 
Ocriplasmin liquefies the vitreous and resolves adhesions at the vitreomacular 
interface,13,15 but it does not exert the kind of tractional force that can be 
achieved during macular surgery. It seems logical then that ocriplasmin may be 
less effective when there is firm or broad adhesion, as might occur with large 
areas of VMA. While spontaneous separation of ERMs is reported,17,18 it is rare 
in adults, suggesting that ERMs have relatively firm adhesion at the macula. 
Given that VMT is often continuous with an ERM, the ERM may serve to anchor 
VMA.  
 
We identified several other factors that appear to influence the response to 
ocriplasmin. Younger patients were more likely to respond, as were phakic eyes. 
It might instead have been expected that older patients are more responsive to 
ocriplasmin than younger patients, given that the vitreous becomes more 
synergetic with age,19 with a weakening of VMA.20 Likewise, it might be expected 
that cataract surgery weakens vitreous attachment and promotes PVD,21-23 which 
occurs in up to three-fourths of patients with an attached vitreous after routine 
phacoemulsification surgery.24 However, eyes that fail to develop PVD despite 
increasing age and cataract surgery may have firmer VMA, such that they are 
less likely to respond to ocriplasmin. Therefore, the worse response in older 
patients and pseudophakic eyes may reflect a selection bias.  
 
Small FTMHs were more likely to close than holes with an apical diameter of 
>250 µm. This is consistent with the literature on FTMH closure following 
vitrectomy, with several authors reporting higher closure rates for small holes.25-28 
 
Strengths of this study include the randomized, double-masked, placebo-
controlled trial design. Responder analyses should be interpreted with caution, 
and the results used to generate hypotheses that can be tested in further studies, 
rather than to draw firm clinical conclusions. 
 
Nonetheless, this study may help to refine case selection for eyes with 
symptomatic VMA/VMT, with or without FTMHs ≤400 µm. The results suggest 
that we should target patients with focal VMA and avoid those with an ERM. For 
eyes with FTMH we should target small holes (≤250 microns) rather than large 
ones. 
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Figure Titles/Legends 
 
Figure Titles 
Figure 1. Representative OCT Images 
Figure 2. Baseline Features Predictive of Vitreomacular Adhesion Resolution 
Figure 3. Subgroup Analysis of Vitreomacular Adhesion Resolution 
Figure 4. Baseline Features Predictive of Full-Thickness Macular Hole Closure 
Figure 5. Subgroup Analysis of Full-Thickness Macular Hole Closure 
 
 
Figure Legends 
Figure 1. Optical coherence tomography (OCT) images of vitreomacular 
adhesion (VMA) at baseline showing: (A) broad adhesions (>1500 μm), (B) focal 
adhesions (≤1500 μm), and (C) full-thickness macular hole (FTMH) with VMA. 
 
Figure 2. Forest plot showing the baseline features predictive of vitreomacular 
adhesion (VMA) release 28 days following treatment. The figure presents the 
mean odds ratios ± 95% confidence interval. Therefore, if the error bars lie to the 
right of 1 there is a significant difference favoring the first comparator (A, of A vs 
B). The figure shows younger patients were more likely to respond, as were eyes 
that were phakic, without an epiretinal membrane (ERM), with VMA ≤1500 
microns, or with a full-thickness macular hole (FTMH).  
 
BCVA, best-corrected visual acuity; DR, diabetic retinopathy; LCL, lower 
confidence limit; OR, odds ratio; TG-MV-006 and TG-MV-007, the two pivotal 
ocriplasmin trials; UCL, upper confidence limit. A plus sign (+) denotes that the 
feature was present, and a negative sign (-) that it was not. 
 
Figure 3. The graph shows the percentages of patients with vitreomacular 
adhesion (VMA) resolution at day 28 in subgroups of participants with baseline 
features independently predictive of response. Error bars show Clopper-Pearson 
95% confidence intervals. 
 
ERM, epiretinal membrane; FTMH, full-thickness macular hole; VMA, 
vitreomacular adhesion. 
 
Figure 4. The figure shows whether the baseline features were predictive of 
nonsurgical full-thickness macular hole (MH) closure at month 6, in a multivariate 
logistic regression model adjusted for baseline covariates.  
 
LCL, lower confidence limit; MH, macular hole; OR, odds ratio; UCL, upper 
confidence limit.  
 
Figure 5. The graph shows the proportion of participants with FTMH closure at 
month 6 in subgroups of participants with baseline features independently 
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predictive of response. Error bars show Clopper-Pearson 95% confidence 
intervals. 
 
FTMH, full-thickness macular hole. 
 
 
 
  
14 
 
 
 
 
 
 
 
 
 
 
  
15 
 
Figure 2. Baseline Features Predictive of Vitreomacular Adhesion Resolution 
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Figure 3. Subgroup Analysis of Vitreomacular Adhesion Resolution 
 
 
 
 
 
 
 
 
 
 
 
 
  
17 
 
Figure 4. Baseline Features Predictive of Full-Thickness Macular Hole Closure 
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Figure 5. Subgroup Analysis of Full-Thickness Macular Hole Closure 
 
 
 
 
 
 
 
 
 
 
